Breast cancer isn’t a single disease. It’s a group of cancers classified by where they start, whether they’ve spread, and which molecular markers drive their growth. Understanding the type matters because it directly shapes treatment options and outcomes. When breast cancer is caught at a localized stage, the five-year relative survival rate is 100%. That number drops to 87.5% for regional spread and 33.8% for distant metastasis, making early detection and accurate typing critical.
Non-Invasive vs. Invasive Breast Cancer
The most fundamental distinction is whether cancer cells have stayed in place or broken through into surrounding tissue. Non-invasive breast cancer, also called stage 0 or carcinoma in situ, means the abnormal cells remain confined to their original location. The most common form is ductal carcinoma in situ (DCIS), where abnormal cells line the milk ducts but haven’t pushed past the duct walls. DCIS is not life-threatening on its own, but without treatment it can progress to invasive cancer.
Invasive breast cancer means cells have broken through the duct or lobule walls and entered surrounding breast tissue. From there, they have the potential to reach lymph nodes and other organs. Any invasive breast cancer is classified as at least stage I.
Invasive Ductal Carcinoma
Invasive ductal carcinoma, now formally called “breast cancer of no special type,” is by far the most common form, representing over 80% of all breast cancer diagnoses in the United States each year. It begins in the cells lining the milk ducts and then grows into the fatty tissue of the breast. Because it tends to form a hard, distinct lump, it’s often detectable on mammograms and during physical exams. Treatment depends heavily on the tumor’s molecular profile, which determines whether hormonal therapy, targeted drugs, or chemotherapy will be most effective.
Invasive Lobular Carcinoma
Invasive lobular carcinoma (ILC) accounts for 10% to 15% of new breast cancer diagnoses. It starts in the lobules, the small glands that produce milk, and has a distinctly different growth pattern from ductal cancer. ILC tumor cells lack a protein called E-cadherin, which normally helps cells stick together. Without it, lobular cancer cells spread diffusely through the breast in thin, unconnected lines rather than clustering into a solid mass.
This growth pattern creates a real diagnostic challenge. ILC tumors don’t usually form lumps you can feel during a self-exam, and they’re harder to detect on standard mammograms. Many cases require MRI for accurate imaging. Despite being harder to find, ILC tends to be hormone receptor-positive, which means it often responds well to hormonal treatments.
Molecular Subtypes and Receptor Status
Beyond where a tumor starts, doctors classify breast cancer by which receptors sit on the surface of its cells. Three markers matter most: estrogen receptors (ER), progesterone receptors (PR), and a protein called HER2. The combination of these markers determines which treatments can target the cancer and gives a clearer picture of how it’s likely to behave.
Hormone Receptor-Positive Cancers
Cancers that test positive for estrogen receptors, progesterone receptors, or both are called hormone receptor-positive. These are the most common molecular subtype. They grow in response to the body’s hormones, which means treatments that block or lower hormone levels can slow or stop their growth. Hormone receptor-positive cancers are further divided into subtypes based on how fast the cells are dividing. Slower-growing tumors (sometimes called luminal A) generally have a better prognosis and may need less aggressive treatment, while faster-growing hormone-positive tumors (luminal B) may benefit from chemotherapy in addition to hormonal therapy.
HER2-Positive Breast Cancer
About 15% to 20% of breast cancers produce too much HER2 protein, which fuels rapid cell growth. HER2-positive cancers were once considered especially aggressive, but targeted drugs that block the HER2 protein have dramatically improved outcomes over the past two decades. These cancers may or may not also have hormone receptors.
A newer classification, HER2-low, identifies tumors that produce some HER2 protein but not enough to qualify as HER2-positive by traditional testing. This category has become clinically important because a newer class of targeted therapy can now treat HER2-low metastatic breast cancer, opening options for patients who previously had fewer targeted treatments available.
Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for about 10% to 15% of all breast cancers. The cells test negative for estrogen receptors, progesterone receptors, and HER2 protein. Because none of those three targets are present, hormonal therapies and HER2-targeted drugs don’t work against it. Chemotherapy has traditionally been the primary treatment, though immunotherapy and other newer approaches are expanding options.
TNBC tends to grow and spread more quickly than hormone receptor-positive cancers and is more common in younger women and Black women. It’s also more frequently linked to inherited BRCA1 gene mutations.
Inflammatory Breast Cancer
Inflammatory breast cancer (IBC) is rare and aggressive, accounting for 1% to 5% of cases. It doesn’t typically present as a lump. Instead, cancer cells block lymph vessels in the skin of the breast, causing distinct symptoms: the skin becomes warm, thickened, and red or purplish, with a dimpled texture that looks like the peel of an orange. The breast may swell rapidly, and the nipple can flatten, crust, or retract.
For a diagnosis of IBC, these skin changes must involve at least one-third of the breast and develop within six months. A biopsy confirming invasive cancer is required. Because IBC spreads quickly, it is always classified as at least stage III at diagnosis, and treatment typically begins with chemotherapy before surgery.
Paget Disease of the Breast
Paget disease of the breast is a rare type that affects the nipple and the darker skin around it (the areola). It usually appears as a scaly, red, itchy rash on the nipple that doesn’t heal, and it’s often mistaken for eczema. Cancer cells from a tumor inside the breast travel through the milk ducts to the nipple surface, though in some cases the cancer may originate at the nipple itself.
Most people diagnosed with Paget disease also have an underlying cancer deeper in the breast. If imaging doesn’t reveal a tumor inside the breast, the diagnosis is typically DCIS (stage 0). However, some people with no visible internal tumor still turn out to have invasive cancer, so thorough evaluation is essential. Prognosis depends largely on whether the underlying cancer is non-invasive or invasive.
Phyllodes Tumors
Phyllodes tumors are rare growths that develop in the connective tissue of the breast rather than in the ducts or lobules. They’re classified into three grades: benign, borderline, and malignant. Benign phyllodes tumors have well-defined borders and low cell activity. Malignant phyllodes tumors show aggressive features, including rapid cell division and irregular borders that infiltrate surrounding tissue. They can even contain elements of other cancers like bone or muscle tumors. Surgery with wide margins is the standard treatment. Unlike most breast cancers, phyllodes tumors rarely respond to hormonal or chemotherapy treatments.
Breast Cancer in Men
Men account for a small percentage of breast cancer cases, but the disease does occur in male breast tissue. The most common types in men are the same as in women: invasive ductal carcinoma and DCIS. Because men have less breast tissue, tumors are often found closer to the nipple. Inherited mutations in BRCA1 and BRCA2 genes increase the risk, with BRCA2 carrying a particularly strong association with male breast cancer. Men with these mutations also face higher risks of prostate and pancreatic cancer. Symptoms in men typically include a painless lump near the nipple, skin changes, or nipple discharge.